[Han Kwangbeom, Edaily Reporter] LOTTE Biologics (Co-CEOs James Park and Shin Yooyeol) announced today that it received a prestigious honor at the 2026 CDMO Leadership Awards, a premier recognition in the global contract development and manufacturing organization (CDMO) industry.



Shin Yooyeol 야마토연타 (fifth from left) and James Park (sixth from left), Co-CEOs of LOTTE Biologics, pose for a commemorative photo with employees after winning the 'Best New or Relaunched CDMO' award at the 2026 CDMO Lea 바다신2릴게임 dership Awards. (Photo: LOTTE Biologics)


The CDMO Leadership Awards, hosted by "Outsourced Pharma" and "Life Science Connect," recognize CDMOs that have demonstrated o 온라인릴게임 utstanding performance over the past 24 months. The evaluation is based on direct feedback from industry professionals across key criteria, including capabilities, compatibility, expertise, quality, r 골드몽게임 eliability, and service.
The awards are widely recognized internationally for their credibility and objectivity, further enhanced this year by the inclusion of an independent evaluation cond 릴게임바다신2 ucted by the Tufts Center for the Study of Drug Development (Tufts CSDD). As nominees are selected solely by clients or industry peers, the program remains independent of marketing or sponsorships, relying entirely on research data and expert judgment.
LOTTE Biologics was named the recipient in the "Best New or Relaunched CDMO" category. This award recognizes companies that have successfully entered or redefined the CDMO market through clear strategic direction and differentiated capabilities, solidifying a strong reputation among global partners.
The company noted that the award reflects its rapid brand expansion in the global market within just four years of launch. It also serves as a direct validation of its service quality and execution capabilities from its client base.
Industry observers have highlighted LOTTE Biologics’ "dual-site strategy" as a key driver of its success. This strategy is supported by the company's extensive experience with over 62 global regulatory approvals and its expanding ADC (antibody-drug conjugate) capabilities, which have significantly bolstered customer confidence.
Building on the upcoming completion of its Songdo Bio Campus 제1공장 (Plant 1) this August, LOTTE Biologics plans to accelerate its portfolio expansion from monoclonal antibodies to ADCs, reinforcing its position as a key player in the next-generation biopharmaceutical market.
A company representative stated, "This award is particularly meaningful as it reflects the recognition we have earned within a short period in the global CDMO market. We will continue to strengthen our role and responsibility as a partner that delivers tangible value to the global biopharma ecosystem, moving beyond mere quantitative growth."
Meanwhile, during DCAT Week, LOTTE Biologics is operating a private meeting room at the Lotte New York Palace Hotel, engaging in strategic discussions with global big pharma and biotech firms to expand its partnership network.
한광범 (totoro@edaily.co.kr)